
ARUP Laboratories | National Reference Laboratory
ARUP provides reference laboratory testing for hospitals and health centers, serving the diagnostic needs of patients. We also consult on lab management, utilization, and operations.
Testing Specialties - ARUP Laboratories
Testing Specialties This page highlights our testing specialties, test updates, testing resources, compliance statements, and experts.
The Association for Diagnostics and Laboratory Medicine To …
Jul 21, 2025 · The Association for Diagnostics and Laboratory Medicine (ADLM) and the Academy of Diagnostics and Laboratory Medicine (ADLM Academy) have recognized ARUP …
ARUP Laboratories ARUP is a nonprofit clinical laboratory enterprise of the University of Utah Department of Pathology
The FDA's Final Rule on Laboratory-Developed Tests: FAQs
What does the FDA’s final rule on LDTs change? The rule makes it explicit that in vitro diagnostics (IVDs) that are manufactured by clinical laboratories—i.e., laboratory-developed tests …
Magnify Summer 2025 | ARUP Laboratories
Although cancer incidence in those older than 50 years has declined in recent years, a concerning upward trend has emerged as incidence in younger populations has increased. But the news …
Education - ARUP Laboratories
We apply our academic expertise to improve patient care by providing over 145,000 continuing education credits annually for clients, physicians, and laboratory professionals at no cost, …
Careers | ARUP Laboratories
Equal Opportunity Employer ARUP Laboratories is an equal opportunity employer. We provide equal employment opportunities to all applicants and employees. We do not discriminate on …
ARUP Resources on the FDA’s Final Rule on Laboratory-Developed …
A Federal Court Judge Vacated in Its Entirety the FDA’s Final Rule on Lab-Developed Tests The rule and its compliance deadlines are no longer in effect, benefiting patient care, innovation, …
Laboratory Testing for Alzheimer’s Disease | ARUP Laboratories
ARUP Laboratories is prioritizing innovation in diagnostics for Alzheimer’s disease and other neurodegenerative diseases to make testing more broadly available to clinicians and patients.